
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
KOR-3 CRISPR/Cas9 KO Plasmid (h) | sc-402526 | 20 µg | $397.00 |
OPRL1 encodes the nociceptin/orphanin FQ receptor (also termed KOR-3), a class A GPCR that couples primarily to Gi/Go to suppress adenylyl cyclase activity, reduce cAMP signaling, and modulate ion channel conductance. Receptor activation regulates synaptic transmission and neuronal excitability, influencing neuropeptide-mediated control of pain processing, stress responsivity, reward circuitry, and autonomic functions. Downstream signaling intersects with MAPK/ERK pathways, β-arrestin–dependent trafficking, and receptor desensitization/internalization processes that shape cellular responses over time. Altered OPRL1/KOR-3 signaling has been associated with neuropsychiatric and neurobehavioral phenotypes, making it relevant for mechanistic studies of neural network regulation and GPCR signaling dynamics.
KOR-3 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the OPRL1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the OPRL1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the OPRL1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish KOR-3 protein expression.
This CRISPR knockout system enables efficient generation of OPRL1-deficient cell models for investigation of KOR-3 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
CRISPRs +/- HDRs
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.